Agios Pharmaceuticals Stock (NASDAQ: AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) Stock, Quote.Headers.trade-ideas

AGIOS PHARMACEUTICALS INC

Agios Pharmaceuticals

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

AGIO

Biotech

Earnings

News

Health Care

General

Agios&#39; mitapivat met its primary endpoint in a Phase 3 trial for PK deficiency in children. The company plans a marketing application based on the results.

Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years

The Tesla Trade

Intraday Update

Markets

Movers

AEHR

ASAN

AVGO

BTDR

CIFR

EWTX

MARA

QUBT

RGTI

SGMO

TSLA

VRDN

WULF

Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday

Exit From HP

Downgrades

Pre-Market Outlook

Analyst Ratings

Trading Ideas

BMBL

CLDX

UDMY

This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals Inc

Legal

Press Releases

FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Agios to Present at the TD Cowen 45th Annual Healthcare Conference  on March 3, 2025

Agios to Present at Upcoming Investor Conferences

Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

BIIB

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Apogee Therapeutics

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Beam Therapeutics

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Denali Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Galapagos NV - American Depositary Shares

Galapagos

ImmunityBio

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Janux Therapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Kymera Therapeutics

Mesoblast Limited - American Depositary Shares

Mesoblast

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MannKind

Soleno Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vericel

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

HC Wainwright & Co.

RBC Capital

Scotiabank

Raymond James

Leerink Partners

Alnylam Pharmaceuticals

Comments

Agios Pharmaceuticals

Agios Pharmaceuticals (NASDAQ:AGIO) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga